Articles tagged with: Vidaza
Results of a small prospective study conducted at the Lee Moffitt Cancer Center suggest that pre-transplant treatment with Vidaza may improve the outcomes of donor stem cell transplantation in higher-risk myelodysplastic syndromes patients.
Patients in the study received a median of three cycles of Vidaza (azacitidine) before proceeding to high-dose chemotherapy followed by a donor stem cell transplant. The Vidaza was administered to each patient while a stem cell donor was sought on their behalf.
About half of the patients had previously been treated with Vidaza or Dacogen (decitabine), a …
Results from a recent retrospective analysis conducted in Spain show that treatment with Vidaza is feasible, and can have important benefits, in myelodysplastic syndromes patients at least 75 years of age.
Forty percent of the patients in the study – who were all 75 years of age or older – achieved transfusion independence. In addition, achieving transfusion independence was associated with more than just an improvement in quality of life. Patients in the study who achieved transfusion independence had a median overall survival twice as long as those who did …
A sub-analysis of results from a recent Phase 1/2 study shows that the investigational drug mocetinostat in combination with Vidaza is highly active in myelodysplastic syndromes patients.
In particular, the results show that 64 percent of the patients in the study, who had intermediate- and high-risk myelodysplastic syndromes (MDS), responded to treatment, with 50 percent achieving a complete response.
In addition, 33 percent of patients achieved transfusion independence.
Dr. Guillermo Garcia-Manero from the M.D. Anderson Cancer Center in Houston presented the results during a poster session at the American Society of Hematology …
Results of a recent Phase 2 study indicate that Zolinza in combination with Vidaza is effective and safe in intermediate- and high-risk myelodysplastic syndromes patients.
Overall, 75 percent of patients in the trial responded to the two-drug regimen, and 35 percent achieved a complete response. According to the study’s lead investigator – Dr. Lewis Silverman from the Tisch Cancer Institute in New York City – these response rates are superior to those seen for treatment with Vidaza (azacitidine) alone. Single-agent Vidaza had an overall response rate of 49 percent in a key trial, …
Yesterday was the final day of this year’s American Society of Hematology (ASH) meeting, which took place in New Orleans.
Sessions throughout the day on Monday and yesterday featured a wide range of interesting presentations about myelodysplastic syndromes (MDS).
For example, initial results of a Phase 2 study of Zolinza (vorinostat) in combination with Vidaza (azacitidine) show that three-quarters of patients responded to the treatment combination and the median overall survival was 27.6 months, which is greater than what has been observed with Vidaza alone.
Another study showed that the …